Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
O14672
UPID:
ADA10_HUMAN
Alternative names:
CDw156; Kuzbanian protein homolog; Mammalian disintegrin-metalloprotease
Alternative UPACC:
O14672; B4DU28; Q10742; Q92650
Background:
Disintegrin and metalloproteinase domain-containing protein 10, also known as ADAM10, plays a pivotal role in cellular processes including proteolytic release of cell-surface proteins and cleavage of amyloid precursor protein (APP). Its activity is crucial for the development and maturation of various tissues, including the vasculature and the nervous system. ADAM10's involvement in cleaving cell adhesion molecules and cytokine receptors underscores its multifaceted role in biological systems.
Therapeutic significance:
ADAM10's link to diseases such as Reticulate acropigmentation of Kitamura and Alzheimer disease 18 highlights its potential as a therapeutic target. Its role in the proteolytic processing of APP and contribution to the amyloidogenic pathway suggest that modulating ADAM10 activity could offer new avenues for treating Alzheimer's disease. Understanding the role of ADAM10 could open doors to potential therapeutic strategies for these conditions.